New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also ...

Personalized vaccines are currently being investigated for the treatment of patients with kidney cancer; however, the ...

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

Cancer’s future may lie in combination therapy—pairing treatments to outsmart tumors, boost survival, and bring new hope ...

Data show that the cancer vaccine Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival in ...

In the Phase III trial, the combination of Padcev and Keytruda improved event-free survival and overall survival in MIBC.

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab ...

Schrödinger announced it will discontinue clinical development of the CDC7 inhibitor SGR-2921 for acute myeloid leukemia (AML) and myelodysplastic syndromes following two patient deaths in an ...

New first-line option for patients with pMMR and dMMR tumours in England NICE has recommended KEYTRUDA (pembrolizumab) with ...